Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
· *The **Sudan** Ebola** and Marburg **mAb** programs were awar**d**ed **approximately **$**190** million of BARDA funding..
GlobeNewswire